A Health Policy and Bioethics Consortium

The Trans-Pacific Partnership (TPP) Agreement is intended to facilitate trade among 12 Asia-Pacific countries including the US, but its progress has been obstructed in part by ongoing controversy over provisions regarding intellectual property protections for pharmaceutical products. Some argue that if signed, the TPP will impact the availability or cost of essential medicines in low-income settings worldwide by requiring all countries to provide high levels of IP protections mirroring current US standards.

Join us as we discuss the implications of the TPP for US patients (and patents), and the proper role of public health concerns in international trade negotiations.

Experts

Learn more about the Health Policy and Bioethics Consortia.

The Health Policy and Bioethics Consortia are hosted and organized by the Harvard Medical School Center for Bioethics and the Program On Regulation, Therapeutics, And Law (PORTAL) at Brigham and Women’s Hospital, in collaboration with the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and the Harvard Program in Therapeutic Science. This monthly series convenes international experts from different fields or vantage points to discuss how biomedical innovation and health care delivery are affected by various ethical norms, laws, and regulations. Support provided by the Oswald DeN. Cammann Fund at Harvard University.